Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases
H Li, J Zuo, W Tang - Frontiers in pharmacology, 2018 - frontiersin.org
Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain
cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and …
cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and …
Asthma outcomes: exacerbations
BACKGROUND: The goals of asthma treatment include preventing recurrent exacerbations.
Yet there is no consensus about the terminology for describing or defining “exacerbation” or …
Yet there is no consensus about the terminology for describing or defining “exacerbation” or …
The asthma–COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?
Most research of treatments for airways diseases has been restricted to patients who meet
standard definitions of either chronic obstructive pulmonary disease (COPD) or asthma, yet …
standard definitions of either chronic obstructive pulmonary disease (COPD) or asthma, yet …
Novel approaches to the management of noneosinophilic asthma
NC Thomson - Therapeutic advances in respiratory disease, 2016 - journals.sagepub.com
Noneosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It
is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of …
is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of …
Benralizumab: a unique IL-5 inhibitor for severe asthma
LD Tan, JM Bratt, D Godor, S Louie… - Journal of Asthma and …, 2016 - Taylor & Francis
The presence of eosinophilic inflammation is a characteristic feature of chronic and acute
inflammation in asthma. An estimated 5%–10% of the 300 million people worldwide who …
inflammation in asthma. An estimated 5%–10% of the 300 million people worldwide who …
Phosphodiesterase-4 inhibitor therapy for lung diseases
Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the breakdown of
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …
JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease
Objective To provide an overview of janus kinase (JAK), chemoattractant receptor
homologous molecule expressed on TH 2 cells (CRTH2), and phosphodiesterase 4 (PDE4) …
homologous molecule expressed on TH 2 cells (CRTH2), and phosphodiesterase 4 (PDE4) …
Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
GM Gauvreau, LP Boulet, C Schmid-Wirlitsch… - Respiratory …, 2011 - Springer
Abstract Background Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic
adenosine monophosphate (cAMP), leading to regulation of inflammatory cell functions …
adenosine monophosphate (cAMP), leading to regulation of inflammatory cell functions …
[HTML][HTML] Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis
MK Park, JR Fontana, H Babaali… - … vasculitis, and diffuse …, 2009 - ncbi.nlm.nih.gov
Results Except for one patient, primary endpoints were not reached in POF-treated patients.
Therefore, a post hoc analysis was performed. The observed relative risk reduction for flares …
Therefore, a post hoc analysis was performed. The observed relative risk reduction for flares …
β2-Agonist Induced cAMP Is Decreased in Asthmatic Airway Smooth Muscle Due to Increased PDE4D
T Trian, JK Burgess, K Niimi, LM Moir, Q Ge, P Berger… - PloS one, 2011 - journals.plos.org
Background and Objective Asthma is associated with airway narrowing in response to
bronchoconstricting stimuli and increased airway smooth muscle (ASM) mass. In addition …
bronchoconstricting stimuli and increased airway smooth muscle (ASM) mass. In addition …